Breast Cancer With High TIL Levels: Skip the Trastuzumab?Breast Cancer With High TIL Levels: Skip the Trastuzumab?
A provocative study suggests that HER2 breast cancer patients with high levels of stromal tumor infiltrating lymphocytes may not need trastuzumab (Herceptin). Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2 | Herceptin | Study